Clinical trials: AIDS-Related Kaposi Sarcoma
HIV-Associated Malignant Neoplasm, HIV Infections
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
This study is being done to understand how many people with HIV (PWH) present for cancer care across the AIDS Malignancy Consortium in the United States and if there are reasons that some PWH choose to participate, or not in…
- Conditions
- HIV-Associated Malignant Neoplasm, HIV Infections, Cancer, AIDS Related Lymphoma
- Trial name
- NCT05510908
- Testing
- Non-Interventional, Non-Interventional Follow-up
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 460 people
- Sponsor
- AIDS Malignancy Consortium
Kaposi's Sarcoma
PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma
RATIONALE: PTC299 may stop the growth of Kaposi sarcoma by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of PTC299 and to see how well it works in treating patients…
- Trial name
- NCT00686842
- Testing
- VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- AIDS Malignancy Consortium
AIDS-Related Kaposi Sarcoma, HIV Infection
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
This phase I trial studies the best dose and effects of NT-I7 in treating Kaposi sarcoma in patients with or without HIV. NT-I7 works by using a patient's immune system to fight cancer.
- Conditions
- AIDS-Related Kaposi Sarcoma, HIV Infection, Kaposi Sarcoma
- Trial name
- NCT04893018
- Testing
- Efineptakin alfa
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Fred Hutchinson Cancer Center
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have…
- Conditions
- AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma
- Trial name
- NCT02595866
- Testing
- Antiretroviral Therapy, Biopsy, Biospecimen Collection
- Where
- 12 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
HIV-1 Infection, Kaposi's Sarcoma
Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma
AIDS-related Kaposi's sarcoma (AIDS-KS) occurs in persons with HIV infection who are also infected with the Kaposi's sarcoma herpesvirus (KSHV).
- Trial name
- REACT-KS (NCT01352117)
- Testing
- efavirenz/emtricitabine/tenofovir disoproxil fumarate, etoposide
- Where
- 8 sites in Brazil, Kenya and 4 more
- Volunteers
- 192 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Sarcoma
Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with HIV-related…
- Trial name
- NCT00090987
- Testing
- imatinib mesylate
- Where
- 15 sites in United States
- Volunteers
- 30 people
- Sponsor
- AIDS Malignancy Consortium
Kaposi's Sarcoma, HIV Infections
Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
This study will examine the safety and effectiveness of the experimental drug bevacizumab for treating both non-acquired immune deficiency syndrome (AIDS) and AIDS-associated Kaposi's sarcoma (KS).
- Conditions
- Kaposi's Sarcoma, HIV Infections, HIV Seronegativity
- Trial name
- NCT00055237
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00474994
- Testing
- sunitinib malate
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
AIDS-Related Kaposi Sarcoma, Human Immunodeficiency Virus 1 Positive
Evaluating Quality of Life in Patients With AIDS-Associated Kaposi Sarcoma Treated With Bleomycin and Vincristine
This pilot phase I trial studies how well treatment with vincristine and bleomycin affect quality of life in patients with acquired immunodeficiency syndrome (AIDS)-associated Kaposi sarcoma.
- Trial name
- NCT03596918
- Testing
- Bleomycin Sulfate, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- Tanzania
- Volunteers
- 10 people
- Sponsor
- AIDS Malignancy Consortium
Kaposi's Sarcoma
Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)
The purpose of this pilot study is to determine whether Maraviroc is effective in the treatment of Kaposi's Sarcoma (KS), when it does not remit with standard antiretroviral drug therapy.
- Trial name
- NCT01276236
- Testing
- Maraviroc
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of California, San Francisco
AIDS-Related Kaposi Sarcoma, Recurrent Kaposi Sarcoma
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
This phase I/II trial studies the side effects and best dose of lenalidomide and to see how well it works in treating patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS).
- Trial name
- NCT01057121
- Testing
- Lenalidomide
- Where
- 13 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)